Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Total Current Assets
All assets expected to be converted to cash or used up within one year.
Forte Biosciences, Inc.NASDAQ: FBRX
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 38.1% from a year ago
Total current assets stood at $65.11M at the end of Q1 FY2026, up 38.1% from a year earlier and down 19.2% from the prior quarter. Over 3 fiscal years it compounded at +24.7% a year.
Context
- Total current assets amounted to 96.9% of total assets at the end of Q1 FY2026, down 2.5 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +38.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 80.59M USD
- Year-over-year change
- +31.4%
- 4-year CAGR
- +17.3%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 80.59M | +31.4% |
| FY2024 | 2024-12-31 | 61.35M | +60.1% |
| FY2023 | 2023-12-31 | 38.33M | -7.7% |
| FY2022 | 2022-12-31 | 41.51M | -2.4% |
| FY2021 | 2021-12-31 | 42.52M | — |
Total Current Assets vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +38.1% is the 2nd highest of 10, against a peer median of -22.6%.
- Total current assets amounts to 96.9% of total assets for FBRX, versus a peer median of 89.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $235.89M USD | -13.1% | -7.8% | 63.4% | |
| Mar 2026 | $215.08M USD | -41.3% | -28.4% | 89.6% | |
| Mar 2026 | $179.53M USD | -27.7% | -25.4% | 63.0% | |
| Mar 2026 | $143.57M USD | +4.5% | +40.5% | 99.4% | |
| Mar 2026 | $134.27M USD | +32.9% | -6.7% | 85.9% | |
| Mar 2026 | CHF 82.68M CHF | -39.6% | -27.6% | 94.6% | |
| Mar 2026 | $65.11M USD | +38.1% | +24.7% | 96.9% | |
| Mar 2026 | $47.34M USD | -42.8% | -18.6% | 96.3% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $16.2M USD | -22.6% | +21.7% | 71.4% |
ACTUActuate Therapeutics Inc | Mar 2026 | $8.52M USD | +100.5% | -12.7% | 95.6% |
| Peer median (excluding FBRX) | — | -22.6% | -12.7% | 89.6% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.